

Tandem announces Australia, New Zealand distribution deals

24 April 2018 | News

Under the terms of the arrangements, the diabetes divisions of AMSL and NZMS will perform all sales, marketing, and customer training and support for Tandem's products in the regions.



Singapore - Tandem Diabetes Care, a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, announced that it has entered into distribution agreements with Australasian Medical & Scientific Ltd (AMSL) and New Zealand Medical & Scientific Ltd (NZMS) to commercialize Tandem's t:slim X2 Insulin Pump in Australia and New Zealand, respectively.

"Partnering with key international distributors furthers our mission to expand available insulin pump choices for people with diabetes worldwide," said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. "AMSL and NZMS have significant experience introducing a variety of diabetes-specific products to patients and healthcare providers in Australia and New Zealand, and we look forward to working with them to bring the t:slim X2 Insulin Pump to the communities they serve."

Under the terms of the arrangements, the diabetes divisions of AMSL and NZMS will perform all sales, marketing, and customer training and support for Tandem's products in the regions. Timing for availability of Tandem products in Australia and New Zealand has not yet been announced.